Accessibility StatementSkip Navigation INCHEON, South Korea, Oct. 28, 2025 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today announced its financial results for the third quarter of fiscal year 2025. "Our third quarter results reflect the solid foundation we have built through operational excellence and disciplined execution," said John Rim, CEO and President of Samsung Biologics. "We continue to prioritize standardization and sca ...

, /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), today unveiled ExellenSÂ – an optimized manufacturing framework applied across the company's biomanufacturing network. Developed through Samsung Biologics' cumulative expertise in plant design, digitalization, and operational excellence, ExellenSstandardizes equipment, processes, and functional specifications to ensure that every facility operates with the same precision. The framework ...